Press Releases Context Therapeutics Inc. Nasdaq

Equities

US21077P1084

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2024 BST			5-day change	1st Jan Change
2.19 ^USD	-0.45%		+12.89%	+93.81%

05-08	Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-06	Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results	05-08	AQ
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update	10/08/23	AQ
Context Therapeutics to Participate in Two August 2023 Investor Conferences	01/08/23	AQ
Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update	13/06/23	AQ
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN	06/06/23	AQ
CONTEXT THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	02/06/23	AQ
Testicular Cancer Pipeline Assessment, FDA Approvals, Clinical Trials, Emerging Drugs, and Therapeutics Assessment 2023 \| Major Companies - Sanofi, Seagen Inc., BioNTech, Seagen, and Others	16/05/23	AQ
Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting	24/04/23	AQ
CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	22/03/23	AQ
CONTEXT THERAPEUTICS INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities (form 8-K)	22/03/23	AQ
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates	22/03/23	AQ
Context Therapeutics announces positive responses in Phase 2 OATH clinical trial	07/02/23	AQ
CONTEXT THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)	06/02/23	AQ
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer	06/02/23	AQ
CONTEXT THERAPEUTICS INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	27/01/23	AQ
CONTEXT THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)	04/01/23	AQ
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones	04/01/23	AQ
CONTEXT THERAPEUTICS INC. : Regulation FD Disclosure, Other Events (form 8-K)	08/12/22	AQ
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers	06/12/22	AQ
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers	06/12/22	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Context Therapeutics Inc. Nasdaq

Equities

US21077P1084

Press Releases

Filters